Pharming Gets FDA Approval For Joenja In Children With APDS

Pharming Group said the FDA approved Joenja (leniolisib) for APDS patients aged 4 to 11 who weigh at least 27 kg. The expanded pediatric indication broadens the addressable population for the rare-disease therapy and is a meaningful positive regulatory catalyst for Pharming.